TIAA CREF Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

TIAA CREF Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$15.6M	Buy	588,512 +257,921	+78%	+$6.11M	0.01%	819
2018 Q4	$6.46M	Sell	330,591 -11,545	-3%	-$226K	0.01%	1207
2018 Q3	$6.7M	Sell	342,136 -126,215	-27%	-$2.4M	﹤0.01%	1373
2018 Q2	$7.76M	Sell	468,351 -27,694	-6%	-$422K	0.01%	1314
2018 Q1	$7.04M	Sell	496,045 -5,692	-1%	-$84.1K	﹤0.01%	1341
2017 Q4	$7.33M	Sell	501,737 -44,797	-8%	-$629K	﹤0.01%	1363
2017 Q3	$6.93M	Buy	546,534 +88,754	+19%	+$1.13M	﹤0.01%	1414
2017 Q2	$5.43M	Sell	457,780 -2,967	-0.6%	-$36.9K	﹤0.01%	1545
2017 Q1	$6.81M	Sell	460,747 -26,936	-6%	-$436K	﹤0.01%	1387
2016 Q4	$7.89M	Sell	487,683 -14,873	-3%	-$270K	0.01%	1286
2016 Q3	$9.11K	Sell	502,556 -1,411	-0.3%	-$27.6K	0.01%	1184
2016 Q2	$8.3M	Buy	+503,967	New	+$8.15M	0.01%	1174
2015 Q4	–	Sell	-21,742	Closed	-$431K	–	3152
2015 Q3	$431K	Sell	21,742 -134,052	-86%	-$4.24M	﹤0.01%	2926
2015 Q2	$5.41M	Sell	155,794 -146,917	-49%	-$4.48M	﹤0.01%	1623
2015 Q1	$7.86M	Hold	302,711	–	–	0.01%	1314
2014 Q4	$3.9M	Sell	302,711 -14,455	-5%	-$181K	﹤0.01%	1806
2014 Q3	$3.9M	Buy	317,166 +25,932	+9%	+$301K	﹤0.01%	1794
2014 Q2	$4.61M	Buy	291,234 +63,254	+28%	+$903K	﹤0.01%	1747
2014 Q1	$3.45M	Sell	227,980 -5,320	-2%	-$60.1K	﹤0.01%	1887
2013 Q4	$1.78M	Buy	233,300 +7,727	+3%	+$41.7K	﹤0.01%	2322
2013 Q3	$762K	Buy	225,573 +17,947	+9%	+$47.3K	﹤0.01%	2778
2013 Q2	$511K	Buy	+207,626	New	+$498K	﹤0.01%	2929

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TIAA CREF Investment Management's HZNP Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 78% in Q1 2019, buying an estimated $6.11M and bringing the position to 588,512 shares worth $15.6M. The position accounts for 0.01% of the portfolio, ranked #819.

TIAA CREF Investment Management first reported a position in HZNP in Q2 2013 and has held it in 22 quarters since. 297 funds tracked by Wall St. Rank hold HZNP as of Q1 2019.

TIAA CREF Investment Management held 588,512 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $15.6M as of Q1 2019.
TIAA CREF Investment Management bought 257,921 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2019, an estimated $6.11M.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #819 holding.
TIAA CREF Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and has held it in 22 quarters since.
297 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.